Chinese biotech startup Excalipoint Therapeutics has officially launched with a substantial $68.7 million in seed funding, positioning itself to accelerate the development of its promising pipeline of six T-cell engager (TCE) therapies. The company, operating under a NewCo model, secured this significant capital infusion through an oversubscribed seed funding round, signaling strong investor confidence in its innovative approach to tackling complex immunological and oncological challenges.
The initial seed funding tranche amounted to $41 million, garnered from a consortium of leading Chinese investors including Apricot Capital, HSG, and Yuanbio Venture Capital, alongside contributions from four other undisclosed entities. This initial success was followed by a subsequent extension round, which brought in an additional $27.7 million. Notably, this extension round saw participation from prominent global venture arms, specifically Lilly Asia Ventures, the venture capital arm of global pharmaceutical giant Eli Lilly and Company, and Eisai Innovation, the investment arm of Japanese pharmaceutical firm Eisai. The backing from such influential players underscores the strategic importance and potential of Excalipoint’s therapeutic focus.
Excalipoint Therapeutics aims to leverage this robust financial foundation to advance its six-strong pipeline of TCE therapies, which are designed to address a range of solid tumor indications and immunological diseases. A core objective of the company’s strategy is to overcome common hurdles associated with current TCE therapies, particularly the challenge of transforming "cold" tumors, which are less responsive to immune attack, into "hot" tumors. This involves a sophisticated approach to manipulating the tumor microenvironment, thereby enhancing the efficacy of T-cell mediated immunity.
At the forefront of Excalipoint’s pipeline is EXP011, a clinical-stage trispecific antibody. This innovative molecule is engineered to simultaneously target DLL3, CD3, and 4-1BB, thereby orchestrating a multi-pronged attack against cancer cells. EXP011 is currently undergoing evaluation in a Phase I/II clinical trial targeting DLL3-expressing malignancies. The trial, which commenced patient dosing in October 2025, is exploring the therapeutic potential of EXP011 in crucial indications such as non-small cell lung cancer (NSCLC) and neuroendocrine tumors. The selection of these indications is strategic, given the significant unmet need and the established role of DLL3 as a target in these cancers.
The genesis of Excalipoint Therapeutics is rooted in the combined expertise of its co-founders, CEO Lei Fang and CFO & CBO Jielun Zhu. Both individuals bring a wealth of experience from their previous leadership roles at I-Mab Biopharma, a prominent China-based biopharmaceutical company. Lei Fang served as an Executive R&D Director at I-Mab for five years, from 2015 to 2020, accumulating deep insights into drug discovery and development. Jielun Zhu previously held the position of Head of Healthcare in Asia for the global investment bank Jefferies, providing him with extensive knowledge of the financial landscape and strategic deal-making within the healthcare sector. This leadership team’s background suggests a strategic orientation towards both scientific innovation and astute business development.
Looking ahead, Jielun Zhu articulated the company’s strategic vision, emphasizing a strong focus on fostering growth through cross-border partnerships and out-licensing agreements. This approach aligns with the evolving trends in the global biopharmaceutical industry, where collaborative models are increasingly crucial for maximizing the potential of novel therapeutic platforms.
The Rise of Chinese Biopharma and Strategic Licensing Deals
The emergence of Excalipoint Therapeutics is taking place against a backdrop of significant growth and increasing global influence of the Chinese biopharmaceutical sector. In recent years, there has been a discernible surge in licensing deals between Chinese companies and their Western counterparts. Data indicates that in 2024, large pharmaceutical companies have in-licensed approximately 28% of their innovator drugs from Chinese biopharma entities. This trend is particularly noteworthy as China now accounts for one-fifth of all drugs currently in development globally, according to a comprehensive report by GlobalData.
This escalating engagement is partly driven by the approaching "patent cliff," a critical period where a significant number of blockbuster drugs lose patent protection, leading to a decline in revenue for pharmaceutical companies. GlobalData projects that the proportion of global drug sales protected by patents will significantly decrease from 12% in 2022 and 6% in 2024 to just 4% by 2030. This impending challenge necessitates a robust pipeline of new, innovative therapies, making drugs originating from emerging markets like China increasingly attractive acquisition targets.
Chinese companies are increasingly adopting the "NewCo" strategy when engaging in deals with Western partners. This model involves establishing a new, often independently managed entity to advance specific drug candidates or platforms. This approach allows the originating Chinese company to offload development costs and risks while simultaneously securing capital through out-licensing agreements for global sales. This not only facilitates the efficient progression of promising assets but also allows Chinese biotechs to retain strategic control and capture value.
Excalipoint’s Strategic Position in the TCE Landscape
T-cell engager (TCE) therapies represent a rapidly advancing frontier in cancer immunotherapy. These bispecific or trispecific antibodies are designed to bridge T cells and tumor cells, effectively redirecting the immune system’s cytotoxic machinery to eliminate cancer. The ability of TCEs to induce potent and targeted anti-tumor responses has made them a key focus for drug developers.
However, the development of TCEs is not without its challenges. Factors such as tumor antigen heterogeneity, the immunosuppressive nature of the tumor microenvironment, and potential on-target, off-tumor toxicities can limit their efficacy. Excalipoint’s stated mission to address these challenges by "turning cold tumors hot" and modulating the tumor microenvironment positions the company to tackle some of the most intractable aspects of cancer treatment.
The DLL3/CD3/4-1BB targeting mechanism of EXP011 is particularly sophisticated. DLL3 is a transmembrane protein that is highly expressed in small cell lung cancer and neuroendocrine tumors, making it a validated therapeutic target. The CD3 component is crucial for engaging T cells, activating them to recognize and attack the cancer cells. The addition of the 4-1BB co-stimulatory ligand engagement is designed to further enhance T-cell activation and persistence, potentially leading to more durable anti-tumor responses and mitigating the risk of T-cell exhaustion. This multi-targeting approach suggests a nuanced understanding of T-cell biology and tumor immunology.
The Broader Implications for Oncology and Immunotherapy
The successful funding and strategic focus of Excalipoint Therapeutics highlight several key trends in the biopharmaceutical landscape. Firstly, it underscores the growing maturity and innovation within the Chinese biotech sector, which is increasingly transitioning from a manufacturing-centric model to one of pioneering drug discovery and development. Secondly, it demonstrates the continued global appetite for novel immunotherapy approaches, with TCEs emerging as a highly promising class of therapeutics.
The company’s emphasis on addressing the tumor microenvironment and overcoming resistance mechanisms is critical for expanding the reach of immunotherapy. As researchers gain a deeper understanding of the complex interplay between tumor cells and the immune system, therapies that can modulate these interactions are likely to achieve greater clinical success. Excalipoint’s pipeline, particularly with EXP011, appears well-positioned to contribute to this evolving paradigm.
The involvement of Lilly Asia Ventures and Eisai Innovation in the funding round suggests that these major pharmaceutical players are actively scouting for promising early-stage assets with the potential for significant clinical and commercial impact. Their investment provides not only financial backing but also the potential for future strategic collaborations, including co-development, licensing, or even acquisition opportunities. This can be invaluable for a nascent biotech company, offering pathways to accelerate drug development and navigate the complex regulatory and commercialization processes.
As Excalipoint Therapeutics progresses its pipeline, the biopharmaceutical industry will be closely watching its clinical trial results. Positive outcomes, particularly in challenging indications like NSCLC and neuroendocrine tumors, could validate its therapeutic approach and further solidify the role of TCEs in the oncology armamentarium. The company’s strategic commitment to partnerships and out-licensing also suggests a business model that could foster further innovation and collaboration within the global drug development ecosystem. The success of Excalipoint could serve as a blueprint for other emerging biotechs seeking to translate cutting-edge science into impactful therapies for patients worldwide. The company’s journey from launch to clinical advancement will be a key indicator of the future direction of TCE development and the broader impact of Chinese innovation on global health.
Leave a Reply